Market cap
$547 Mln
Revenue (TTM)
$117 Mln
P/E Ratio
--
P/B Ratio
43.8
Div. Yield
0 %
Key Ratios and Highlights
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -60,469.21 | -36,881.76 | -180.11 | -200.26 | 9.29 |
| Net Margin
| -- | -1,613.12 | -184.24 | -- | -- |
| Return on equity
| -36.88 | -10.00 | -339.88 | -92.33 | 3.28 |
| Return on Capital
| -30.52 | 6.99 | -- | -73.29 | 3.28 |
| Return on Assets
| -22.95 | -27.03 | -52.54 | -50.47 | 2.74 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.84 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
--
|
--
|
-73.29
|
3.28
|
-21.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-339.88
Lower than Peers by 299.59
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
-339.88
|
-339.88
|
-92.33
|
3.28
|
-21.59
|
|
Peer Median
|
-40.29
|
--
|
--
|
--
|
--
|
ROA
-52.54
Lower than Peers by 21.70
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
-52.54
|
-52.54
|
-50.47
|
2.74
|
-21.13
|
|
Peer Median
|
-30.84
|
--
|
--
|
--
|
--
|
EBIT Margin
-180.11
Lower than Peers by 97.89
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
-180.11
|
-180.11
|
-200.26
|
9.29
|
-181,216.67
|
|
Peer Median
|
-82.21
|
--
|
--
|
--
|
--
|
Net Margin
-184.24
Lower than Peers by 94.36
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
-184.24
|
-184.24
|
-203.25
|
8.97
|
-181,216.67
|
|
Peer Median
|
-89.88
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Higher than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
0.00
|
0.00
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
4.08
Lower than Peers by 49.95
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
4.08
|
4.08
|
-0.05
|
2,970.63
|
-0.98
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
-341.22
Lower than Peers by 340.27
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
-341.22
|
-341.22
|
-2,136.92
|
115.24
|
-56.75
|
|
Peer Median
|
-0.95
|
--
|
--
|
--
|
--
|
Net Profit Growth
-7.94
Lower than Peers by 0.76
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
-7.94
|
-348.66
|
-2,241.76
|
114.71
|
-56.75
|
|
Peer Median
|
-7.19
|
--
|
--
|
--
|
--
|
EPS Growth
-344.10
Lower than Peers by 358.53
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
-344.10
|
-344.10
|
-22.28
|
1.14
|
-0.53
|
|
Peer Median
|
14.43
|
--
|
--
|
--
|
--
|
Book Value Growth
-93.56
Lower than Peers by 83.10
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
-93.56
|
-93.56
|
--
|
--
|
--
|
|
Peer Median
|
-10.46
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
--
|
--
|
0.84
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
--
|
--
|
0.01
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.48
Lower than Peers by 2.33
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
3.48
|
3.48
|
7.28
|
14.26
|
96.85
|
|
Peer Median
|
5.80
|
--
|
--
|
--
|
--
|
Quick Ratio
3.28
Lower than Peers by 2.41
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
3.28
|
3.28
|
7.06
|
14.04
|
96.85
|
|
Peer Median
|
5.69
|
--
|
--
|
--
|
--
|
Interest Coverage
-27.66
Lower than Peers by 25.57
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
-27.66
|
-27.66
|
-64.94
|
--
|
--
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
40.06
Higher than Peers by 21.08
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
40.06
|
40.06
|
31.26
|
10.28
|
2,650.00
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
Asset Turnover
0.29
Higher than Peers by 0.22
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
0.29
|
0.29
|
0.25
|
0.31
|
0.00
|
|
Peer Median
|
0.07
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
--
|
--
|
76.95
|
20.40
|
10,981.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
--
|
--
|
121.44
|
46.30
|
-2,524.23
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
--
|
--
|
139.45
|
94.43
|
6,049.14
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
--
|
--
|
58.94
|
-27.73
|
2,408.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
--
|
--
|
-6.70
|
129.21
|
-9.69
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
43.75
Higher than Peers by 38.40
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
43.75
|
43.75
|
10.05
|
4.02
|
2.28
|
|
Peer Median
|
5.35
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-9.88
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
-9.88
|
-9.88
|
-5.97
|
86.01
|
-5.50
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
547
Higher than Peers by 400
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
547
|
547
|
--
|
--
|
--
|
|
Peer Median
|
147
|
--
|
--
|
--
|
--
|